| Your Space |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Medicine > New Merck Vaccine Produces Serious Bowel Problems for Infants |
|
Your Space - New Merck Vaccine Produces Serious Bowel Problems for Infants
According to a Reuters report, the Food and Drug Administration stated that it wo According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product uld be notifying consumers and health care providers alerting them to some 28 cas ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in s where infants suffered serious bowel conditions after receiving Merck’s new vac lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ine to protect against rotavirus. The report from Reuters said, “The FDA said it here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe was not immediately clear how many of the 28 reported cases were caused by the va d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro cine. It said the condition, known as intussusception, can occur in the absence o ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc f vaccination.” The FDA said at least 3.5 million doses of Merck’s vaccine have easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi lready been delivered in the United States since its release in February of 2006. nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically The FDA said that the 28 cases filed with the agency is not enough to recall the and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ vaccine, but they have issued a warning and are waiting to hear of any further ca ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi es to be reported. Intussusception is the intestines get blocked or twisted, res ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ulting in one portion to telescope into another portion causing intestinal blocka dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod e. This causes very strong abdominal pain and if not treated with the first 24 h cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin urs, can cause permanent damage to the abdominal tissue, long term intestinal pro tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen lems, or even death. Dr. Michelle Goveia told reports at Reuters, “it would be d t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel fficult to determine how many, if any, of the 28 cases of intussusception reporte ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust d under the surveillance system were due to the Merck vaccine. But she speculated y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products most were naturally occurring cases, given the product's safety in the large clin . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de cal trials.” Check out this site for more information on ordering from online elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip target="_new" href="http://www.freebeeforeignpharmacy.com">foreign pharmacies tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:What Is A Good Bookkeeper Worth? Looking to Sell a Healthcare Company - Consider an M&A Advisor Personal Finance - Searching Google Resources For Family Business
|